{"ok":true,"trend":{"id":436753,"platform":"news","region":"global","key":"oral small-molecule glp-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial","title":"Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial","url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Eam1fWVVoVi1QbjdNOEZhQUEwRzRaM2k4S29qdDk4Z0lSVlU1SVJtbFNjNW44SHlqU1JkNGF6YkZINDRzeV9vRldvVTV0bUtQNEJjbGl3RlI0YnZpaUdz?oc=5","first_seen":"2026-09-30T03:38:30.564375Z","last_seen":"2026-09-30T14:34:52.294654Z","last_rank":25,"peak_rank":2,"last_volume":null,"peak_volume":0,"seen_count":9,"score":9.5725,"category_hint":"medicine","section":"health","category":"medicine","summary":"A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.","why":"GLP-1 drugs are a major focus of diabetes and obesity treatment, and an effective oral pill would be a significant step forward.","tone":"neutral","entities":["safiglipron","Nature","type 2 diabetes"],"summarized_at":"2026-09-30T15:42:03.716148Z","meta":{"via":"scan","lang":"en","term":"medicine","source":"Nature","published":"Tue, 29 Sep 2026 21:29:45 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Oral GLP-1 pill safiglipron shows promise in early type 2 diabetes trial","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-30T03:38:30.564375Z","rank":2,"volume":null},{"captured_at":"2026-09-30T05:00:36.805213Z","rank":3,"volume":null},{"captured_at":"2026-09-30T06:22:52.532462Z","rank":3,"volume":null},{"captured_at":"2026-09-30T07:44:52.582735Z","rank":3,"volume":null},{"captured_at":"2026-09-30T09:06:53.894595Z","rank":3,"volume":null},{"captured_at":"2026-09-30T10:28:53.107499Z","rank":3,"volume":null},{"captured_at":"2026-09-30T11:50:55.351445Z","rank":3,"volume":null},{"captured_at":"2026-09-30T13:12:53.045472Z","rank":5,"volume":null},{"captured_at":"2026-09-30T14:34:52.294654Z","rank":25,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Eam1fWVVoVi1QbjdNOEZhQUEwRzRaM2k4S29qdDk4Z0lSVlU1SVJtbFNjNW44SHlqU1JkNGF6YkZINDRzeV9vRldvVTV0bUtQNEJjbGl3RlI0YnZpaUdz?oc=5","author":"Nature","title":"Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial","snippet":null,"posted_at":"2026-09-29T21:29:45Z","likes":null}],"elsewhere":[],"window":"7d"}}